BRPI0518484A2 - composiÇço, cÁpsula, e, processo para preparar a mesma - Google Patents
composiÇço, cÁpsula, e, processo para preparar a mesmaInfo
- Publication number
- BRPI0518484A2 BRPI0518484A2 BRPI0518484-3A BRPI0518484A BRPI0518484A2 BR PI0518484 A2 BRPI0518484 A2 BR PI0518484A2 BR PI0518484 A BRPI0518484 A BR PI0518484A BR PI0518484 A2 BRPI0518484 A2 BR PI0518484A2
- Authority
- BR
- Brazil
- Prior art keywords
- capsule
- composition
- surfactant
- hlb
- preparing same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSIÇçO, CÁPSULA, E, PROCESSO PARA PREPARAR A MESMA. A N- [1S,2S]-3 -(4-clorofenil)-2-(3 -cianofenil)- 1 -metilpropil] - 2-metil-2- { [5 -trifluorometil]piridina-2-il } áxi } propanamida (Composto 1) melhorou surpreendentemente a solubilidade e a biodisponibilidade em um veículo lipofilico que compreende um óleo digerivel, farmaceuticamente aceitável, um tensoativo ou, um co-solvente ou, uma mistura de quaisquer de dois ou mais destes. Em uma forma de realização da presente invenção existe composições auto-emulsificantes ou auto-microemulsificantes que compreendem 1) Composto 1; 2) um tensoativo que tem um HLB de 1 a 8; e 3) um tensoativo que tem um HLB de mais de 8 a 20; e opcionalmente, 4) um óleo digerivel e/ou co-solvente e/ou antioxidante ou conservante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63074604P | 2004-11-24 | 2004-11-24 | |
PCT/US2005/041836 WO2006057903A2 (en) | 2004-11-24 | 2005-11-18 | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518484A2 true BRPI0518484A2 (pt) | 2008-11-18 |
Family
ID=36498432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518484-3A BRPI0518484A2 (pt) | 2004-11-24 | 2005-11-18 | composiÇço, cÁpsula, e, processo para preparar a mesma |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070298099A1 (pt) |
EP (1) | EP1817012A2 (pt) |
JP (1) | JP2008521807A (pt) |
KR (1) | KR20070084531A (pt) |
CN (1) | CN101065115A (pt) |
AU (1) | AU2005309808A1 (pt) |
BR (1) | BRPI0518484A2 (pt) |
CA (1) | CA2587733A1 (pt) |
IL (1) | IL183309A0 (pt) |
MX (1) | MX2007006183A (pt) |
NO (1) | NO20073224L (pt) |
RU (1) | RU2007123366A (pt) |
WO (1) | WO2006057903A2 (pt) |
ZA (1) | ZA200703532B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160184258A1 (en) * | 2005-11-07 | 2016-06-30 | Murty Pharmaceuticals, Inc. | Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
US9265724B2 (en) * | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
AU2016203127B2 (en) * | 2005-11-07 | 2018-07-12 | Murty Pharmaceuticals, Inc | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
MY153288A (en) * | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
JP2010502703A (ja) * | 2006-09-06 | 2010-01-28 | メルク エンド カムパニー インコーポレーテッド | 置換アミドの経口投与のための液体及び半固体の医薬製剤 |
US20090041839A1 (en) * | 2007-05-23 | 2009-02-12 | Beasley Martin W | Pharmaceutical compositions for the treatment of pain |
PL2192893T3 (pl) * | 2007-08-21 | 2015-12-31 | Basilea Pharmaceutica Ag | Kompozycja przeciwgrzybicza |
BRPI0909185A2 (pt) | 2008-03-20 | 2015-08-25 | Virun Inc | Derivado de vitamina e e seus usos |
DK2548456T3 (en) | 2008-03-20 | 2015-09-28 | Virun Inc | Emulsions including (comprising) a PEG derivative of tocopherol |
EP2111854A1 (en) * | 2008-04-22 | 2009-10-28 | Lek Pharmaceuticals D.D. | Self-microemulsifying systems incorporated into liquid core microcapsules |
US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
WO2010019255A1 (en) * | 2008-08-13 | 2010-02-18 | Virun, Inc. | Compositions containing aminoalkanes and aminoalkane derivatives |
WO2010044093A1 (en) * | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
US20110082205A1 (en) * | 2009-10-01 | 2011-04-07 | Panker Cynthia A | Docosahexaenoic Acid Gel Caps |
US9320295B2 (en) | 2010-03-23 | 2016-04-26 | Virun, Inc. | Compositions containing non-polar compounds |
WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
JP2013209294A (ja) * | 2010-07-30 | 2013-10-10 | Meiji Seikaファルマ株式会社 | 液状医薬組成物 |
EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
WO2013120025A1 (en) | 2012-02-10 | 2013-08-15 | Virun, Inc. | Beverage compositions containing non-polar compounds |
BR112015015864B1 (pt) * | 2013-01-14 | 2022-08-23 | Infirst Healthcare Limited | Uso de uma composição farmacêutica no tratamento de uma condição de dor severa |
BR112015015858B1 (pt) * | 2013-01-14 | 2023-02-28 | Infirst Healthcare Limited | Uso de uma composição farmacêutica de solução sólida no tratamento de uma inflamação crônica |
WO2014117999A1 (en) * | 2013-02-04 | 2014-08-07 | Biocopea Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
CA2950670A1 (en) * | 2014-06-17 | 2015-12-23 | Merck Sharp & Dohme B.V. | Stable formulations of testosterone undecanoate |
US10799479B2 (en) | 2015-04-10 | 2020-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of DIM-related indoles |
WO2016162229A1 (en) * | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
MX2017001714A (es) * | 2017-02-07 | 2018-08-06 | Rhein Siegfried Sa De Cv | Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla. |
WO2018219804A1 (en) * | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
CA3134550A1 (en) | 2019-04-11 | 2020-10-15 | R.P. Scherer Technologies, Llc | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
KR100602725B1 (ko) * | 1998-12-11 | 2006-07-20 | 파마솔루션스, 인코포레이티드 | 물에서 불충분하게 용해되는 약제를 위한 자가-유화용조성물 |
JP2000256323A (ja) * | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
FR2804015B1 (fr) * | 2000-01-21 | 2005-12-23 | Oreal | Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations |
US6562822B2 (en) * | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
DE10107261B4 (de) * | 2001-02-16 | 2005-03-10 | Merck Patent Gmbh | Pharmazeutische Zusammensetzung |
GB2391471B (en) * | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
US8535716B2 (en) * | 2004-04-01 | 2013-09-17 | Tsrl, Inc. | Methods and composition of extended delivery of water insoluble drugs |
US20100216848A1 (en) * | 2007-10-10 | 2010-08-26 | Peresypkin Andrey V | Liquid pharmaceutical compositions for parenteral administration of a substituted amide |
-
2005
- 2005-11-18 KR KR1020077011766A patent/KR20070084531A/ko not_active Application Discontinuation
- 2005-11-18 BR BRPI0518484-3A patent/BRPI0518484A2/pt not_active IP Right Cessation
- 2005-11-18 RU RU2007123366/15A patent/RU2007123366A/ru not_active Application Discontinuation
- 2005-11-18 AU AU2005309808A patent/AU2005309808A1/en not_active Abandoned
- 2005-11-18 CN CNA2005800403069A patent/CN101065115A/zh active Pending
- 2005-11-18 US US11/667,344 patent/US20070298099A1/en not_active Abandoned
- 2005-11-18 WO PCT/US2005/041836 patent/WO2006057903A2/en active Application Filing
- 2005-11-18 CA CA002587733A patent/CA2587733A1/en not_active Abandoned
- 2005-11-18 JP JP2007543271A patent/JP2008521807A/ja not_active Withdrawn
- 2005-11-18 MX MX2007006183A patent/MX2007006183A/es unknown
- 2005-11-18 EP EP05824856A patent/EP1817012A2/en not_active Withdrawn
-
2007
- 2007-05-02 ZA ZA200703532A patent/ZA200703532B/xx unknown
- 2007-05-17 IL IL183309A patent/IL183309A0/en unknown
- 2007-06-22 NO NO20073224A patent/NO20073224L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006057903A3 (en) | 2006-07-20 |
RU2007123366A (ru) | 2008-12-27 |
KR20070084531A (ko) | 2007-08-24 |
US20070298099A1 (en) | 2007-12-27 |
IL183309A0 (en) | 2007-09-20 |
JP2008521807A (ja) | 2008-06-26 |
CA2587733A1 (en) | 2006-06-01 |
MX2007006183A (es) | 2007-09-11 |
WO2006057903A2 (en) | 2006-06-01 |
ZA200703532B (en) | 2008-09-25 |
NO20073224L (no) | 2007-08-23 |
CN101065115A (zh) | 2007-10-31 |
EP1817012A2 (en) | 2007-08-15 |
AU2005309808A1 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0518484A2 (pt) | composiÇço, cÁpsula, e, processo para preparar a mesma | |
US20200222360A1 (en) | Stable cannabinoid compositions | |
AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
IL189310A0 (en) | Intravenous propofol emulsion compositions having preservative efficacy | |
ATE516016T1 (de) | Selbstemulgierende formulierungen von cetp- hemmern | |
CY1110261T1 (el) | Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα | |
MX357759B (es) | Formulaciones y formas de dosificacion de fosfolipidos oxidados. | |
CA3116971A1 (en) | Topical minocycline foamable compositions | |
MX2019003698A (es) | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. | |
AU2003285143A8 (en) | Analysis of pharmaceutical solubility and stability | |
DE60222580D1 (de) | Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung | |
KR20040068308A (ko) | 아제티딘 유도체를 기본으로 하는 약제학적 조성물 | |
CN105534745A (zh) | 一种乳化组合物及其在制备油水互溶型天然迷迭香抗氧化剂中的应用 | |
US8779000B1 (en) | Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production | |
JP5855349B2 (ja) | 油性製剤 | |
JP2018517784A (ja) | デュタステリドを含有する医薬組成物及びそれを含むカプセル製剤 | |
MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
US20190015329A1 (en) | Pharmaceutical formulation | |
MY140556A (en) | Clear pharmaceutical aqueous microemulsion comprising propofol and process for preparation | |
BR0302523A (pt) | Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease | |
AU2016209917B2 (en) | Galenic formulation comprising a topical drug | |
CA2734284C (en) | Pyrazolone derivative formulations | |
AR053333A1 (es) | Composiciones farmaceuticas orales y parenterales que contienen altas concentraciones de agentes solubilizantes aromaticos | |
JP2014516946A (ja) | エザチオスタットとの賦形剤適合性 | |
RU2006115446A (ru) | Состав для стабилизации липидов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |